The DNp63 protein, a product of the TP63 gene that lacks the N-terminal domain, has a critical role in the maintenance of self renewal and progenitor capacity in several types of epithelial tissues. DNp63 is frequently overexpressed in squamous cell carcinoma (SCC) and in some other epithelial tumours. This overexpression may contribute to tumour progression through dominantnegative effects on the transcriptionally active (TA) isoforms of the p53 family (TAp63, TAp73 and p53), as well as through independent mechanisms. However, the molecular basis of DNp63 overexpression is not fully understood. Here, we show that the expression of DNp63 is regulated by the Wnt/b-catenin pathway in human hepatocellular carcinoma (HCC) and SCC cell lines. This regulation operates in particular through TCF/LEF sites present in the P2 promoter of TP63. In addition, we show that DNp63 and b-catenin are frequently coexpressed and accumulated in oesophageal SCC, but not in HCC. These results suggest that activation of the b-catenin pathway may contribute to overexpression of DNp63 during tumour progression, in a cell type-specific manner.
Introduction
p53 is the founding member of a family of proteins that also comprises p63 and p73. All three proteins are transcription factors that control partially overlapping and interconnected genomic programs, such as cell-cycle arrest or apoptosis (Moll and Slade, 2004) . These proteins are expressed as multiple isoforms due to alternative splicing and promoter usage (Yang et al., 1998; Yang and McKeon, 2000; Marcel and Hainaut, 2009 ). Most of the isoforms possess a central DNAbinding domain, but differ in their N-and C-terminal regions. The N-terminal region contains a transactivation domain present in the so-called transcriptionally active (TA) isoforms, but absent in the truncated (DN) ones. In the case of TP63, TA isoforms are produced from P1 promoter, whereas P2 promoter, located in intron 3, generates DN isoforms (Yang et al., 1998) (Figure 1 ). By competing with TA isoforms for the binding to their responsive elements (REs), DN isoforms prevent target-gene activation, thus behaving as transdominant-negative isoforms (Yang et al., 1998; Petitjean et al., 2008) . Given the similarities in DNA-binding properties between p63, p73 and p53, non-physiological upregulation of DNp63 or DNp73 expression may contribute to the functional inactivation of p53, thereby promoting tumourigenesis in the absence of mutation in p53. DNp63 or DNp73 upregulation can also turn down TAp63 and TAp73 activity, favouring tumour progression independently of p53 inactivation. The notion that the three factors operate through partially independent mechanisms is supported by the cooperative effects of TP63, TP73 and TP53 gene inactivation on tumour formation in transgenic mice (Flores et al., 2002; Flores et al., 2005) . Thus, the transcriptional activity of each p53 family member may depend upon a delicate balance between TA and DN isoforms.
Despite their structural and functional similarities, TP53, TP63 and TP73 present different genetic alterations in human cancer. Although p53 is frequently inactivated by mutation and loss of heterozygosity in many cancer types, mutations in TP73 and TP63 are rare. In contrast, deregulated expression of TP63, resulting in an increased DNp63/TAp63 ratio, is common in epithelial tumours, including all forms of squamous cell carcinomas (SCCs) and some forms of adenocarcinoma (Moll and Slade, 2004) . In these tissues, the expression of TP63 is a hallmark of normal proliferating cells of the basal or myoepithelial layers. In stratified epithelium, p63 is essential for the self renewal of progenitors, as well as their rate of progression towards differentiation (Yang et al., 1999) . Thus, in tumours, the increased DN/TAp63 ratio is likely to provide growth and survival advantages by maintaining cells in a proliferative status that retains some of the characteristics of progenitors (Senoo et al., 2007; Wu et al., 2005; Rocco et al., 2006) . However, the molecular mechanisms that lead to DNp63 overexpression are only partially characterized. DNp63 overexpression has been associated with 3q27-29 amplification, a region encompassing the TP63 gene, in about 20-25% of SCC, but it is also observed in cancers without such an amplification, suggesting that other mechanisms may operate to upregulate this gene in a pathological context .
In the present study, we carried out a survey of TP63 P2 promoter in search of candidate factors for transcriptional regulation of DNp63. In silico analysis revealed the presence of a potential p53RE, previously identified by others (Waltermann et al., 2003; Lanza et al., 2006) , and two TCF/LEF-binding elements (TBEs). TCF/LEF transcription factors are activated through a signalling cascade involving b-catenin, a key protein of the Wnt/b-catenin pathway frequently deregulated in many epithelial cancers, including SCC (Ninomiya et al., 2000; Kudo et al., 2007) . In normal cells, b-catenin is present in the cytoplasm at low levels due to its phosphorylation and its subsequent proteasome-dependent degradation (Novak and Dedhar, 1999; Ninomiya et al., 2000; Kudo et al., 2007) . In tumours, deregulation of the Wnt pathway leads to increased stability of b-catenin, which accumulates and translocates into the nucleus Morin et al., 1997) . Nuclear b-catenin binds to members of the TCF/ LEF family, resulting in the transactivation of genes containing TBE in their promoter, such as CCND1 (Shtutman et al., 1999) , AXIN2 (Jho et al., 2002; Lustig et al., 2002) or PITX2, a paired-related homeobox gene required for the development of several tissues (Kioussi et al., 2002; Ai et al., 2007) .
Here, we demonstrate that the longest DN p63 isoform (DNp63a) and b-catenin bind to and modulate the TP63 P2 promoter activity. Moreover, we show that b-catenin-mediated P2 activation implies multiple non-canonical TBEs. Finally, in line with these results, we describe that DNp63 overexpression correlates with b-catenin delocalization in oesophageal SCC. These results provide novel insights into the mechanism by which TP63 expression is altered in tumours.
Results

Structure of P2 promoter
The putative transcription factor-binding sites present in a 3000 bp region of P2 promoter were identified by using the Matinspector (http://www.genomatix.de) software. Figure 1 shows the structure of the promoter and the position of putative RE (detailed in Supplementary  Figure 1 ). Several regulatory elements located within the TP63 P2 promoter, including a p53RE (Lanza et al., 2006) , a TATA box, three CAAT boxes and a SP1/SP3 site (Romano et al., 2006) , were confirmed in our in silico analysis. However, we failed to identify the STAT3 RE previously reported (Chu et al., 2008) . On the other hand, we identified two putative TBEs and four Pitx2-binding sites (PBSs). The presence of p53RE and TBEs/PBSs suggests that expression of DNp63 may be controlled through two mechanisms of particular relevance in carcinogenesis, one involving auto-and heteroregulatory loops by the p53 family members and the other involving the Wnt/b-catenin pathway and TCF/ LEF factors. On the basis of these considerations, we set out to assess the functionality of TBEs and of the p53RE.
Regulation of P2 promoter by DNp63a protein itself
We previously reported that DNp63 and p53 expression are inversely correlated in hepatocytes and hepatocellular carcinoma (HCC) cell lines , suggesting that p53 might repress DNp63. In fact, repression of the P2 promoter by p53 has further been confirmed in keratinocytes (Lanza et al., 2006) . As DNp63 and p53 share similar DNA-binding specificities (Yang et al., 1998) , we investigated the possibility that DNp63a regulates its own promoter. We first transfected Hep3B cells with a DNp63a-expression vector and evaluated the resulting effect on the expression of the endogenous DNp63. As shown in Figure 2a , an increase of the endogenous DNp63 expression was observed at the mRNA level as compared with control cells, indicating that DNp63a could activate its own promoter. Then, ChIP assay was used to evaluate the ability of DNp63a to bind to P2 promoter. A transfected wildtype p53 and the promoter of WAF1/CIP1 (a wellcharacterized p53-target gene), on which DNp63a is able to bind, were used as positive controls; the GAPDH promoter was used as a negative one. As expected, in p53-transfected Hep3B cells, both WAF1 and P2 fragments were specifically amplified from the fraction immunoprecipitated with the anti-p53 antibody (Figure 2b , left (Figure 2c ). As the TAp63 isoform is expressed at very low levels in the Hep3B cell line under basal conditions , these results demonstrated that exogenous DNp63a binds both to WAF1 and P2 promoters, the latter suggesting that DNp63 expression might be controlled by an autologous feedback mechanism.
We next determined the resulting effect of DNp63a binding on its own promoter and localized the involved Figure 2 DNp63a protein binds to P2 promoter and regulates its expression via the CAAT boxes and independently of the p53RE. Experiments were performed in the p53-null Hep3B cell line transfected with either a wild-type p53-or a DNp63a-expression vector. (a) Reverse transcription-qPCR analysis of endogenous DNp63 expression 48 h after transfection with 5 mg of DNp63a-expression vector by using primers amplifying the DNp63 5 0 UTR. Results are expressed as endogenous DNp63 expression in the presence of exogenous DNp63a ( þ ) relative to empty vector (À) and are mean±s.e.m. from three independent experiments. (b) Binding of p53 (positive control) or DNp63a to TP63 P2 and WAF1 promoters, assessed by ChIP assay using anti-p53 (a-p53) or anti-p63 (a-p63) polyclonal antibodies for p53-and DNp63a-transfected cells, respectively. IgG, non-immune serum. Input, 4% of total DNA extracted before immunoprecipitation. GAPDH promoter amplification was used as negative control. (c) Quantification of DNp63a binding on TP63 P2, WAF1 and GAPDH promoters assessed by ChIP assay and qPCR. Results are presented as fold enrichment with an anti-p63 antibody relative to control immunoglobulin (see materials and methods for details). (d, e) Ability of exogenous DNp63a protein to activate various TP63 P2 promoter constructs. Luciferase activity is presented as fold induction with p53 or DNp63a ( þ ) relative to the empty vector (À) and error bars mean±s.e.m. from three independent experiments. b-catenin-DNp63 axis in tumour progression C Ruptier et al binding sites by testing full-length P2 promoter or deletion mutants by luciferase assay. Although p53 was able to repress the activity of P2 promoter, as already described (Lanza et al., 2006) , an enhanced P2 activity was observed in the presence of DNp63a (Figure 2d ). However, these effects did not require the presence of the putative p53RE, as p53RE-deleted (À740/ þ 139 Dp 53RE) and -truncated (À404/ þ 139) P2 fragments were still activated by DNp63a. Furthermore, although the À740/ þ 139-and À404/ þ 139-truncated fragments differ by the presence of a STAT3 RE required for the self-activation of DNp63 expression (Chu et al., 2006; Chu et al., 2008) , they exhibit similar levels of activity. Actually, DNp63a induction was still observed with a deletion mutant lacking the distal 75% of the P2 promoter, but retaining a proximal segment that contains the CAAT boxes, the SP1 site and the TATA box (À404/ þ 139 fragment). Lanza et al. (2006) identified the CAAT boxes and not the p53RE as the DNA sequences of P2 promoter essential for p53 repression. We thus tested whether the CAAT boxes are required for DNp63-mediated activation of the P2 promoter. Deletion of both the CAAT boxes 2 and 3 resulted in a modest decrease in both p53 repression and DNp63 activation of the P2 promoter (Figure 2e) .
Overall, our results indicate that TP63 P2 promoter activation by DNp63a is independent of the identified p53RE and probably through the CAAT boxes.
DNp63 expression is activated by b-catenin Two putative TBEs have been identified in our in silico analysis, thus suggesting a cross-talk between DNp63 and the Wnt/b-catenin pathway. To test this hypothesis, we overexpressed an exogenous stabilized b-catenin (DN89 deletion mutant) and then quantified DNp63 expression by reverse transcription-qPCR. Endogenous DNp63 expression was significantly upregulated (up to 25-fold) by DN89 b-catenin (Figure 3a ) more strongly than induction of the b-catenin-target gene AXIN2 (Supplementary Figure 2) . This result was in agreement with luciferase assay, in which the increased expression of a P2-driven luciferase gene was observed in the presence of this b-catenin mutant (Supplementary Figure 3A) . Moreover, in ChIP assay, endogenous stabilized b-catenin, but not the wild-type one, was found to bind to the P2 promoter (Figure 3b) . Indeed, qPCR analysis of ChIP assays revealed that immunoprecipitation with an anti-b-catenin antibody results in an enrichment of P2 sequences of 10-, two-and one fold (for HepG2, Hep3B and HuH7, respectively) compared with immunoprecipitation with non-specific immunoglobulin G (data not shown). Finally, knocking down b-catenin expression by siRNA resulted in a statistically significant reduction of DNp63, both at mRNA (30%) and protein levels (Figure 3c ). In agreement with these results, b-catenin extinction also led to a decreased P2 promoter activity, as shown by luciferase assay (Sup- Figure 3B ). Altogether, these results are consistent with the identification of DNp63 as a novel b-catenin-target gene. It should be noted that in vitro, b-catenin is able to activate DNp63 expression in both the cell types used, that is, HCC and SCC.
We next investigated whether the b-catenin-driven effect was mediated through the two canonical TBEs located within the P2 promoter. Neither the deletion of the distal site (À740/ þ 139 fragment) nor the mutation or deletion of the proximal one (À740/ þ 139 TBE2mut and À740/ þ 139 DTBE2 fragments) had a significant influence on P2 promoter activation by b-catenin (Figure 4a) . However, the expression of a TCF4 dominant-negative variant (DNTCF4) reduced the effect of b-catenin on DNp63 expression in a manner similar to its effect on AXIN2 expression (Figure 4b ). This raised the possibility that P2 promoter activation involves noncanonical TBEs (Supplementary Figure 1) . Actually, the combined deletion of the proximal TBE and of noncanonical TBEs (À740/ þ 139 DTBE2,7 and À740/ þ 139 DTBE2,3,4,5,7 fragments) significantly decreased reporter activation (Figure 4c) . These results highlight a 
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C Ruptier et al b-catenin-mediated effect through synergistic action of several binding sites rather than through a single canonical one. Nevertheless, P2 promoter also contains four potential Pitx2-binding sites. PITX2 has been reported as a b-catenin-target gene (Kioussi et al., 2002) . Moreover, in the presence of b-catenin, Pitx2 protein is converted from repressor to activator in a manner similar to TCF/LEF. Therefore, we tested whether DNp63 expression is regulated by Pitx2. For this, we silenced Pitx2 and b-catenin, separately or together, in the Hep3B cell line. We first verified the silencing efficiency both at mRNA (Figure 5a ) and protein (Figures 5b and c) levels and then checked for the expression of DNp63. The extinction of PITX2 expression led to a significant decrease of DNp63, similar to the one obtained with b-catenin inhibition (Figure 5d ). No synergistic effect was observed with the double knockdown, in agreement with the cross-talk between Pitx2 and b-catenin already described (Kioussi et al., 2002) . Overall, our results identify DNp63 as a novel b-catenintarget gene and demonstrate the implication of both canonical and non-canonical TBEs and of Pitx2 in the b-catenin-mediated activation of DNp63 expression.
Concordance between deregulation of b-catenin and DNp63 in human tumours
The results above suggest that activation of b-catenin may contribute to the increased DNp63 expression in tumours. In tumours, the presence of an activated b-catenin is revealed by changes in its localization, that is, a loss of membranous staining and a gain of cytosolic and sometimes nuclear staining. To evaluate the relevance of the b-catenin-DNp63 cross-talk in cancer, we determined whether the b-catenin delocalization is frequently associated with overexpression of DNp63 in human oesophageal SCC, a type of cancer in which overexpression of DNp63 is a common event. In normal oesophageal epithelium, a membrane-restricted b-catenin and a nuclear DNp63 staining were found in cells of basal and parabasal layers (Figure 6, upper panel) . A total of 43 oesophageal SCC were tested for b-catenin and DNp63 staining by immunohistochemistry. Strong nuclear accumulation of DNp63 or change in b-catenin localization was each observed in 35 cases, 33 of them showing both events (Table 1) . Thus, about 76% of oesophageal SCC displayed a concordant alteration of b-catenin localization and strong DNp63 expression, as illustrated in Figure 6 , middle and lower panels, strengthening the notion that alteration of the Wnt/bcatenin pathway might contribute to DNp63 upregulation. 
Discussion
There is growing evidence for a major role of DNp63 in tumour progression. Indeed, beyond its dominantnegative effect on p53 suppressor function, DNp63 was found to favour angiogenesis and chemoresistance (Senoo et al., 2002; Wu et al., 2005; Rocco et al., 2006) and to regulate cell-adhesion processes (Carroll et al., 2006; Yang et al., 2006) . Conversely, several studies reported a loss of p63 expression in metastatic stages (Barbieri et al., 2006; Adorno et al., 2009) . These observations suggest a dual role of DNp63 in tumourigenesis with enhanced expression in the early stages of progression during which the epithelial cell fate is maintained, followed by loss of expression when cells acquire mesenchymal properties associated with metastatic potential. Given this context, identifying the transcription factors that may contribute either to enhance or repress DNp63 expression is of particular interest. To this end, an in silico analysis of the P2 promoter that controls DNp63 expression was performed and one p53RE and two TBEs were identified. We next determined whether either DNp63 itself or b-catenin could regulate the P2 promoter and whether their effects involved the identified binding sites.
We observed a regulation of the P2 promoter by DNp63a itself, which does not implicate the p53RE. Both negative and positive regulation were reported (Harmes et al., 2003; Waltermann et al., 2003; Chu et al., 2006; Romano et al., 2006) , but our results argue in favour of a positive regulation of P2 by DNp63a. It should be noted that activation of P2 by DNp63a was observed in cell lines lacking p53, demonstrating that this activation is not due to a dominant-negative effect of DNp63a on p53-dependent P2 repression. The fact that both factors exert independent and opposite effects leads to multiple regulatory possibilities, complicated by the observation that P2 promoter may be repressed in the presence of small amounts of DNp63a and activated with increasing amounts (Chu et al., 2006) . This high complexity may explain the controversy highlighted above.
The most novel observation in our in silico study is the presence of two canonical TBEs within the P2 promoter. Therefore, we checked whether DNp63 expression was regulated by b-catenin. We showed that overexpression of a stabilized b-catenin increases P2 promoter activity and DNp63 expression. The specificity of DNp63 activation through the b-catenin pathway was confirmed both by silencing b-catenin expression and by inhibiting the b-catenin-TCF transcription factor interaction. However, promoter-deletion studies showed that the effect of b-catenin was mediated through multiple canonical and non-canonical TBEs rather than a single canonical one. The presence of multiple functional TBEs in some putative b-catenin-target genes as AXIN2 has been previously documented (Hatzis et al., 2008) , thus supporting our results.
We observed that DNp63 expression was not completely abolished in the presence of DNTCF4 and that the decrease of P2 promoter-deletion mutant activity only reached a maximum of 60%. This suggests that other transcription factors remained active. One possible candidate was Pitx2, as four Pitx2-binding sites are present in the P2 promoter, which were not removed in the deletion mutants. More than a direct b-catenintarget gene, Pitx2 is also a transcription factor that is converted from repressor to activator in the presence of b-catenin. Indeed, the extinction of PITX2 expression by RNA interference resulted in a decrease of DNp63 expression similar to the one obtained upon b-catenin silencing. Moreover, the double silencing of b-catenin and PITX2 expression did not provide any additional effect, indicating that DNp63 expression required both of these two proteins. Overall, the converging data that we obtained by various technical approaches indicate that DNp63 is a robust transcriptional target of the Wnt/b-catenin pathway through both TCF/LEF and Pitx2 transcription factors.
Two reports about the effect of DNp63 on b-catenin accumulation and activity have been published. One study suggests that overexpressed DNp63 is able to induce b-catenin accumulation by interacting with the complex responsible for b-catenin phosphorylation (Patturajan et al., 2002) . The second one reports an increase of Wnt/b-catenin activity in the presence of overexpressed exogenous DNp63, but an inhibition with endogenous DNp63a, without detectable change in b-catenin level or phosphorylation (Drewelus et al., 2010) . We were not able to detect any increase in b-catenin activity after DNp63 overexpression in our experiments (data not shown). Altogether, these apparent contradictory results strongly suggest that DNp63-b-catenin cross-talk may depend on experimental models and conditions. All our analyses were performed in two different epithelial contexts represented by HCC and SCC cell lines, as 20-30% of these two types of tumours show alterations in the Wnt/b-catenin pathway (Ninomiya et al., 2000; Kudo et al., 2007; Cavard et al., 2008) . We equally used HCC and SCC cell lines with different b-catenin status and did not observe any discrepancy between the two models. But, most of the experiments were performed with high amounts of exogenous protein. This approach can provide important information on molecular mechanisms but, as discussed above, does not reflect in vivo conditions. For this reason, we searched whether the deregulation of the b-catenin (Ninomiya et al., 2000; Taniere et al., 2001; Kudo et al., 2007) . Interestingly, of 43 tumours without TP63 gene amplification analysed, 33 exhibited a concordant expression of DNp63 and delocalization of b-catenin. These results provide pathological support in favour of a role of b-catenin in DNp63 expression in SCC. However, no correlation between these two alterations and the p53 status (wild type, deleted or mutated) was observed, supporting a mechanism independent of the p53 status in this tumour type. Thus, our results suggest first, a link between DNp63 and b-catenin by placing DNp63 downstream from the Wnt/b-catenin pathway and second, a cell type-dependent balance between p53 and b-catenin opposite effects on DNp63 expression.
In conclusion, our results show that expression of DNp63 is dependent upon the status of two main proteins, p53 and b-catenin (Figure 7) . In normal differentiated cells, the presence of a functional p53 and a non-activated Wnt/b-catenin pathway should lead to the inhibition of DNp63 expression. In contrast, in tumour cells containing a non-functional p53 and an activated b-catenin pathway, DNp63 expression may increase and thus favour tumour progression. It must be considered that this scenario is strongly influenced by the type of cell and tumour. In any case, the cross-talk between b-catenin and DNp63 may be of major relevance in the maintenance of normal and cancer epithelial stem cells, a process in which both factors have important roles. In a physiological context, b-catenin and DNp63 regulate proliferation or differentiation of epidermal and mammary progenitor/stem cells (Senoo et al., 2007; Ambler and Maatta, 2009; Pece et al., 2010) . In tumours, they have been implicated in the maintenance of the stemness of cancer stem cells (Katoh and Katoh, 2007; Zucchi et al., 2008) . These observations suggest that the cross-talk between DNp63 and b-catenin may represent a major regulator checkpoint in the initiation, progression and dissemination of tumours of epithelial origin.
Materials and methods
Plasmids and mutagenesis DNp63a, DN89 b-catenin mutant and DNTCF4-expression vectors have been previously described Cavard et al., 2006; Petitjean et al., 2008) . pCMV-p53-expression vector was from Clontech (Mountain View, CA, USA). The pGL3-P2 luciferase reporter plasmid encompassing the -2928/ þ 139 TP63 P2 promoter sequences was kindly provided by Dr A Constanzo (Lanza et al., 2006) . Deletions and mutations of p53RE, TBEs and CAAT boxes were performed by using the Quick change II mutagenesis kit (Agilent, Massy, France). Primer sequences are described in Supplementary Table I. Cell culture Hep3B and HepG2 HCC cells were cultured as previously described . HuH7 HCC cells were cultured in RPMI medium supplemented with penicillin/ streptomycin/glutamine, 10% foetal calf serum, 1% nonessential amino acids and 0.01 M Hepes Buffer (Life Technologies, Illkirch, France). TE-6 and TE-10 oesophageal SCC cell lines were cultured in Dulbecco's modified Eagle medium supplemented with penicillin/streptomycin/glutamine and 10% foetal calf serum (Life Technologies). References and p53 and b-catenin status of cell lines are reported in Supplementary  Table II .
Transient transfections
Expression vectors were introduced by using Lipofectamine 2000 (Life Technologies) and siRNA with Hiperfect transfection reagent (Roche, Meylan, France) or Lipofectamine RNAiMax (Life Technologies).
RNA interference experiments were performed by transfecting 2 Â 10 5 TE-10, HepG2 or Hep3B cells with 6 pmol of siRNA. Total RNA was extracted 24 or 48 h later with TriREAGENT (Sigma, Lyon, France), according to manufacturer's conditions. The following siRNA oligonucleotides were used: control siRNA (sense) 5 0 -GGCAUAGAUGUAGC UGUAA-3 0 , b-catenin siRNA 1 (sense) 5 0 -GGUGCUAUCU GUCUGCUCUAGUAAU-3 0 , b-catenin siRNA 2 (sense) 5 0 -CCACAGCUCCUUCUCUGAGUGGUAA-3 0 , b-catenin siRNA 3 (sense) 5 0 -AGCUGAUAUUGAUGGACAG-3 0 , Pitx2 siRNA (sense) 5 0 -CCAGGCUAUUCCUACAACA-3 0 .
Luciferase assays
Luciferase assays were performed as previously described (Petitjean et al., 2008) , by using 1.8 mg of p53, DNp63a, wildtype or mutant b-catenin-expression vectors, 1 mg of luciferase reporter plasmid, and 0.1 mg of renilla luciferase control plasmid. b-catenin-DNp63 axis in tumour progression C Ruptier et al
